pharma · HIV-1 Infection · HIV-1 infection
Gilead Sciences
Gilead Sciences Pty Limited
Gilead Sciences clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 333 Lakeside Drive, Foster City, CA 94404, US
- Founded
- 1987
- Employees
- 14,602
- Programs
- 30
- Drugs
- 54
- Patents
- 0
Gilead Sciences projects
7 ClinicalTrials.gov programs sponsored by Gilead Sciences.
Gilead Sciences has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
EDGE-Lung
Gilead Sciences Pty Limited
Advanced Non-Small Cell Lung Cancer
1 trial -
GS-4321 PLACEBO
Gilead Sciences Pty Limited
Chronic Hepatitis Delta.
1 trial -
GS-US-409-5704
Gilead Sciences Pty Limited
Ulcerative Colitis (UC)
1 trial -
GS-US-576-6220
Gilead Sciences Pty Limited
Non-small cell lung cancer
1 trial -
GS-US-699-7184-01
Gilead Sciences Pty Limited
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
1 trial -
IMMU-132-06
Gilead Sciences Pty Limited
Locally Advanced/Metastatic Urothelial Cancer
1 trial -
Trodelvy 200 mg powder for concentrate for solution for infusion
Gilead Sciences Pty Limited
Metastatic Solid Tumors
1 trial
Frequently asked questions
How many clinical projects does Gilead Sciences have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.